Clinical Trial Equity Initiatives

By administering investigational therapies in the neoadjuvant setting before surgery, organizations can rapidly assess tumor response and accelerate treatment validation, because early biological changes in the tumor provide faster readouts of drug efficacy than long-term clinical outcomes. This strategy leverages the neoadjuvant window—treatment before surgery—as a biological testing ground to evaluate drug effectiveness in real time, using pathological and imaging biomarkers to measure response within weeks rather than waiting years for recurrence data. Unlike traditional adjuvant trials that require long follow-up periods, this approach shortens the drug evaluation timeline and enables adaptive learning within platform trials like I-SPY 2, making it a cornerstone of precision oncology and adaptive trial design.